Minute Insight: Bioventus Completes Cartiheal Acquisition Following Agili-C Approval
Bioventus exercised a “call option” to acquire Cartiheal for about $315m, plus up to $135m in milestones. The US FDA recently approved Cartiheal’s Agili-C implant to treat knee joint surface lesions.
You may also be interested in...
Smith & Nephew said it will acquire sports medicine technology company Cartiheal for up to $330m to boost its knee injury repair portfolio.
At the live AAOS conference, exhibitors, including major orthopedics players, demoed digital innovations, software-enabled technologies, robotics and smart implants that are expected to create efficiencies in the surgical continuum and provide data to improve outcomes.
Cardio Conversations: ‘Much More Than Just A Patch,’ iRhythm CEO Blackford Talks AI Arrhythmia Diagnostics
iRhythm CEO Quentin Blackford returned to Medtech Insight’s Cardio Conversations podcast to talk about the launch of his company’s new Zio monitor patch supported by a sophisticated neural network. He also addressed the company’s plans to improve its position in the mobile cardiac telemetry market, the impact of pulsed field ablation on the cardiac monitoring business, and more.